RVL Pharmaceuticals plc (NASDAQ:RVLP) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET
Company Participants
Lisa Wilson - In-Site Communications
Brian Markison - Chief Executive Officer
James Schaub - Chief Operating Officer
Michael DePetris - Principal Accounting Officer
Conference Call Participants
Louise Chen - Cantor Fitzgerald
John Vandermosten - Zacks SCR
Michaela Diverio - Barclays
Jorge King - H.C. Wainwright
Operator
Good morning, everyone. My name is Todd, and I will be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals First Quarter 2023 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer period. [Operator Instructions]. As a reminder, this conference call is being recorded today, May 11, 2023.
It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for RVL Pharmaceuticals. Please go ahead.
Lisa Wilson
Thank you, operator. Welcome to RVL Pharmaceuticals First Quarter 2023 Financial Results and Commercial Update Call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison; Chief Operating Officer, JD Schaub; and Principal Accounting Officer, Mike DePetris. This morning, the company issued a press release detailing financial results for the three months ended March 31, 2023. This press release and a webcast of this call can be accessed through the Investors section of the RVL website at rvlpharma.com.
Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to RVL's management as of today and involve risks and uncertainties, including those noted in today's press release and the company's filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements except as required by law.
During this call, we refer to non-GAAP financial measures such as adjusted EBITDA loss. For a reconciliation of adjusted EBITDA loss to net loss, please see the tables at the end of today's press release. The archived webcast of this call will be available for 30 days on RVL's website, rvlpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on Thursday, May 11, 2023. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings.